



# UNITED STATES PATENT AND TRADEMARK OFFICE

10  
UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/754,171	01/09/2004	Suzanne Benedict	PC25144A	8481
28940	7590	04/08/2005		EXAMINER
AGOURON PHARMACEUTICALS, INC. 10350 NORTH TORREY PINES ROAD LA JOLLA, CA 92037			AULAKH, CHARANJIT	
			ART UNIT	PAPER NUMBER
			1625	

DATE MAILED: 04/08/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/754,171	BENEDICT ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Charanjit S. Aulakh	1625	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on \_\_\_\_.
- 2a) This action is FINAL.                  2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-45 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_ is/are allowed.
- 6) Claim(s) 1,2,18-21,24-31 and 33-45 is/are rejected.
- 7) Claim(s) 3-17, 22, 23, 25, 26 and 32 is/are objected to.
- 8) Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
  1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. ____
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date ____	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: ____

## DETAILED ACTION

1. Claims 1-45 are pending in the application.

### ***Claim Rejections - 35 USC § 112***

2. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. Claims 33-45 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The following eight different factors (see *Ex parte Foreman*, 230 USPQ at 547; *Wands*, *In re*, 858.F. 2d 731, 8 USPQ 2d 1400, Fed. Cir. 1988) must be considered in order for the specification to be enabling for what is being claimed:

Quantity of experimentation necessary, the amount of direction or guidance provided, presence or absence of working examples, the nature of the invention, the state of the prior art, the relative skill of those in the art, the predictability or unpredictability and the breadth of claims. In the instant case, the specification is not enabling based on atleast four of the above mentioned eight different factors such as quantity of experimentation necessary, the amount of direction or guidance provided, presence of working examples, the state of the prior art and the breadth of claims.

The instant compounds are inhibitors of protein kinase activity, specifically CHK-1 as shown by in vitro data on page 71. The specification also mentions using various cell

lines for studying the effect of instant compounds in combination with antineoplastic agents in vitro ( see pages 330-331 ) and in vivo using lung and colon cell lines and furthermore, using gemcitabine as a neoplastic agent ( see page 332 ). However, there is no indication or data reported in the specification that combination does indeed produce significant greater cytotoxic effect than the neoplastic agent alone in any cell line. There is no teaching in the prior art showing greater cytotoxic effect of combination of other known CHK-1 inhibitors with any neoplastic agent or radiation. There is no teaching in the prior art or instant specification that CHK-1 inhibitors are known to potentiate the cytotoxic effect of every known neoplastic agent or radiation. There is lot of unpredictability regarding therapeutic effect of protein kinase inhibitors as evidenced by second paragraph on page 2 ( see lines 13-25 ) of instant specification. The instant specification mentions on page 2, lines 22-25 that CHK-1 inhibitors of present invention administered alone or as co-therapy could prove beneficial in the treatment of a number of human diseases, such as cancer. Therefore, based on these teachings, the instant specification calls for further experimentation to validate the efficacy of instant CHK-1 inhibitors in various human diseases. However, there are no working examples present to show the efficacy of instant compounds in known animal models of all known diseases mediated by all known protein kinases such as mentioned in instant claim 43. The instant compounds of formula I encompasses several hundreds of thousands of compounds based on the values of variables X, Y, Z, A, R2, R3 and R4 and therefore, in absence of such teachings, guidance and presence of working examples, it would require undue experimentation to demonstrate the efficacy of instant compounds in

Art Unit: 1625

known animal models of all known diseases mediated by all known protein kinases such as mentioned in instant claims 33-43 and hence their utility in treating all these disease conditions.

4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

5. Claims 2 and 33-45 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 2 recites the limitation "substituted alkyl for variable R3" in claim 1. There is insufficient antecedent basis for this limitation in the claim.

In claims 33-41, the term ---anti-neoplastic agent--- is indefinite since specific agent is not defined.

In claims 42-45, the specific disease condition mediated by specific protein kinase is not defined.

### ***Claim Rejections - 35 USC § 102***

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

6. Claims 1, 2, 18-21, 24, 27-31 and 33-45 are rejected under 35 U.S.C. 102(b) as being anticipated by Webber ( WO 00/42040, cited on applicants form 1449).

Webber discloses tricyclic inhibitors of PARP useful for treating various diseases such as cancer and neurodegenerative diseases alone or in combination with cytotoxic agents and/or radiation. The compounds of formula (III) disclosed by Webber ( see claim 11 on pages 126-127 ) anticipates the instant claims when X represents O, Y-Z

Art Unit: 1625

represents -N=CH and R3 represents an alkyl group in the instant compounds of formula I.

***Allowable Subject Matter***


7. Claims 3-17, 22, 23, 25, 26 and 32 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

8. The petition to correct inventorship by adding two additional inventors has been received and the inventorship has now been corrected.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Charanjit S. Aulakh whose telephone number is (571)272-0678. The examiner can normally be reached on Monday through Friday, 8:30 A.M. to 5:00 P.M..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Cecilia Tsang can be reached on (571)272-0562. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

  
Charanjit S. Aulakh  
Primary Examiner  
Art Unit 1625